Holen Sie sich die Stockscreener-App
23.06
6.60%
-1.63
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
NRIX Maintained by HC Wainwright & Co. -- Price Target Raised to $34 - GuruFocus
Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside - TradingView
NRIX Maintained by Truist Securities -- Price Target Raised to $34.00 - GuruFocus
RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33 - Moomoo
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $28 to $40 - Moomoo
Nurix stock price target raised to $34 by H.C. Wainwright By Investing.com - Investing.com India
Mizuho raises Nurix stock price target to $34 on Roche deal By Investing.com - Investing.com South Africa
Nurix stock price target raised to $34 by H.C. Wainwright - Investing.com UK
Baird reiterates Nurix stock Outperform rating at $33 target By Investing.com - Investing.com India
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside - TradingView
Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX) - Sahm
Nurix Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
NRIX Maintained by Stifel -- Price Target Raised to $40 - GuruFocus
NRIX Maintained by RBC Capital -- Price Target Raised to $33 - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $40.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada - MarketBeat
NRIX Reiterates by BTIG -- Price Target Maintained at $32 - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
RBC Capital Raises Nurix Therapeutics Price Target to $33 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Nurix Therapeutics Reports Q2 Loss, Revenue Falls Short Of Expectations - Bitcoin World
Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates - FXStreet
NRIX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Q2 2026 Earnings: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
Nurix Therapeutics, Inc. Files Form 8-K Announcing July 2026 Press Release and Nasdaq Listing Details - Minichart
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix (NRIX) Reports Q2 Revenue Miss, Highlights Roche Collabora - GuruFocus
Is Nurix Therapeutics Inc (NRIX) Facing Valuation Concerns After - GuruFocus
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Enterprise value to EBIT forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q - Moomoo
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ: NRIX) widens loss but secures $700M Roche bexobrutideg collaboration - Stock Titan
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M - marketscreener.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighWhat's Next? - MarketBeat
Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com - Investing.com South Africa
Nurix Therapeutics stock hits 52-week high at $24.93 - Investing.com
Precision Trading with Nurix Therapeutics Inc. (NRIX) Risk Zones - Stock Traders Daily
Price to sales forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Nurix Therapeutics earnings loom: Roche deal impact in focus By Investing.com - Investing.com South Africa
Nurix Therapeutics earnings loom: Roche deal impact in focus - Investing.com
Nurix stock up 29% in a month: Here's what you should know - MSN
Nurix Therapeutics patents new SMARCA2-targeting PROTACs - BioWorld News
NRIX Q2'26 Earnings: EPS estimate is (0.72) USD - TradingView
Nurix Therapeutics outlines its pipeline strategy - Ad-hoc-news.de
Roche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseases - Select Science
Price to earnings forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
Price to book forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
NRIXNurix Therapeutics Inc Volatility & Greeks - Finviz
Earnings preview: Nurix Therapeutics, Inc. (NRIX) Q2 earnings expected to decline - MSN
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade - MSN
Nurix Therapeutics CLO Christine Ring sells $259,366 in stock By Investing.com - Investing.com India
Form 4 Nurix Therapeutics Inc For: 2 July By Investing.com - Investing.com Australia
Nurix Therapeutics CLO Christine Ring sells $259,366 in stock - Investing.com
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):